Inhaled Iloprost

ApprovedSmall molecule

Bayer

Inhaled Iloprost is one of 155 small molecule programs targeting Respiratory Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

154

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory FailureActive, not recruiting

Pulmonary HypertensionActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Oxidative StressActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

Respiratory FailurePhase 2

Active, not recruiting

Pulmonary HypertensionApproved

Active, not recruiting

Chronic Obstructive Pulmonary DiseaseApproved

Active, not recruiting

Oxidative StressPhase 2

Active, not recruiting

Pulmonary Arterial HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Inhaled Iloprost

Bayer

Approved

2 2

Veramyst

GSK

Preclinical

26 3

Flovent

GSK

Preclinical

6 4

Spiriva

Boehringer Ingelheim

Preclinical

15 5

Aclidinium Bromide

AstraZeneca

Preclinical

21 6

Formoterol Fumarate

AstraZeneca

Preclinical

11 7

Atrovent

Boehringer Ingelheim

Preclinical

5 8

Calciferol

Alnylam Pharmaceuticals

Preclinical

—9

Proventil

Mylan Pharmaceuticals Inc

Preclinical

3 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pulmonary Hypertension2 trials

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Terminated·UUniversity of Chicago·Phase 4·NCT00409526·1 enrolled

Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide

Terminated·—·Phase 4·NCT02170519·27 enrolled

Chronic Obstructive Pulmonary Disease2 trials

Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD)

Unknown status·—·Phase 4·NCT01116063·15 enrolled

Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation

Completed·YYonsei University·N/A·NCT02490657·44 enrolled

Respiratory Failure1 trial

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

Completed·HHamad Medical Corporation·Phase 2·NCT04445246·40 enrolled

One-lung Ventilation1 trial

The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery

Completed·SSeoul St. Mary's Hospital·N/A·NCT03936140·72 enrolled

Heart Transplantation1 trial

Iloprost for Bridging to Heart Transplantation in PH

Withdrawn·HHeidelberg University·Phase 2·NCT02482402

3 more indications

Efficacy1 trial

Efficacy of Ventavis Used in Real-life Setting.

Completed· Bayer logo

Bayer··NCT01355380·55 enrolled

Oxidative Stress1 trial

Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

Completed·LLouisiana State University Health Sciences Center in New Orleans·Phase 2·NCT01941225·24 enrolled

Pulmonary Arterial Hypertension1 trial

The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00302211·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Inhaled Iloprost. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled Iloprost compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled Iloprost. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

Inhaled Iloprost

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pulmonary Hypertension2 trials

Chronic Obstructive Pulmonary Disease2 trials

Respiratory Failure1 trial

One-lung Ventilation1 trial

Heart Transplantation1 trial

Efficacy1 trial

Oxidative Stress1 trial

Pulmonary Arterial Hypertension1 trial

References

Drug Info

Quick Facts

Related News